VanEck Biotech ETF (NASDAQ:BBH) Stock Short Interest Report for October

VanEck Biotech ETF (NASDAQ:BBH – Get Free Report) saw a large increase in short interest during the month of October. As of October 30th, there was short interest totaling 60,902 shares, an increase of 51.2% from the October 15th total of 40,268 shares. Approximately 3.0% of the company’s stock are sold short. Based on an average daily trading volume, of 14,685 shares, the days-to-cover ratio is presently 4.1 days.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. bought a new stake in shares of VanEck Biotech ETF in the 3rd quarter valued at about $24,952,000. Nwam LLC acquired a new position in VanEck Biotech ETF during the second quarter worth approximately $18,614,000. Quantitative Investment Management LLC acquired a new position in VanEck Biotech ETF during the second quarter worth approximately $7,589,000. Bank of America Corp DE raised its stake in VanEck Biotech ETF by 44.3% in the first quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock valued at $12,473,000 after buying an additional 20,375 shares during the period. Finally, Proficio Capital Partners LLC bought a new stake in VanEck Biotech ETF in the second quarter valued at approximately $5,183,000. Institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Price Performance

BBH traded down $1.11 during trading on Tuesday, reaching $247.71. 8,801 shares of the stock were exchanged, compared to its average volume of 8,104. The stock’s 50 day moving average price is $244.18 and its two-hundred day moving average price is $210.06. VanEck Biotech ETF has a twelve month low of $179.25 and a twelve month high of $263.74.

VanEck Biotech ETF Company Profile

(Get Free Report)

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.

See Also

Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.